Citations

Clear

750 citation(s) found for "Lowe, Val".

Decreased Glutamate Levels in Patients with Amnestic Mild Cognitive Impairment: An sLASER Proton MR Spectroscopy and PiB‐PET Study
Zeydan, Burcu , Deelchand, Dinesh K. , Tosakulwong, Nirubol , Lesnick, Timothy G. , Kantarci, Orhun H. , Lowe, Val J. , Jack, Clifford R. , Petersen, Ronald C. , Öz, Gülin , Kantarci, Kejal , Machulda, Mary M. , Knopman, David S. , Jack, Clifford R , Öz, Gülin , Kantarci, Kejal , Zeydan, Burcu , Deelchand, Dinesh K

Mayo Clinic

Journal of Neuroimaging | June 29, 2017 | Volume: 27 | Issue: 6 | Pages: 630-636

10.1111/jon.12454 | PMID 28661060 Get It

ABSTRACTBACKGROUND AND PURPOSEGlutamate levels may be informative about the declining neuronal health in the central nervous system. We used an advanced proton MR spectroscopy (1H‐MRS) protocol composed of semi‐localization by adiabatic selective refocusing (sLASER) localization and FAST(EST)MAP shimming for detection of alterations in brain glutamate concentrations in patients with amnestic mild cognitive impairment.METHODSParticipants with amnestic mild cognitive impairment (n= 14; median age = 80) and age‐ and sex‐matched clinically normal controls (n= 32; median age = 79) from the population‐based Mayo Clinic Study of Aging were recruited prospectively to the 3T single‐voxel1H‐MRS study that examined metabolite changes in the posterior cingulate gyri. To be included, controls had to have low β‐amyloid load on [11C] Pittsburgh Compound B (PiB)‐PET (standard uptake value ratio; SUVr < 1.42) and patients with amnestic mild cognitive impairment had to have high β‐amyloid load (SUVr ≥ 1.42).RESULTSGlutamate concentration and the glutamate/myo‐inositol ratio were lower in patients with amnestic mild cognitive impairment than clinically normal controls (P< .05). Higher global cortical PiB‐PET SUVr correlated with lower glutamate/myo‐inositol (r= –.3,P= .04).CONCLUSIONSThe advanced sLASER with FAST(EST)MAP shimming is a promising protocol for identifying glutamate alterations. Advanced1H‐MRS protocols may add to the understanding of early Alzheimer's disease pathophysiology through detection of glutamate concentration in posterior cingulate gyri of individuals with amnestic mild cognitive impairment.
Insulin differentially affects the distribution kinetics of amyloid beta 40 and 42 in plasma and brain
Swaminathan, Suresh Kumar, Ahlschwede, Kristen M. , Sarma, Vidur , Curran, Geoffry L., Omtri, Rajesh S. , Decklever, Teresa, Lowe, Val J. , Poduslo, Joseph F., Kandimalla, Karunya K. , Kandimalla, Karunya K

Mayo Clinic

Journal of Cerebral Blood Flow & Metabolism | June 1, 2017 | Volume: 38 | Issue: 5 | Pages: 904-918

10.1177/0271678x17709709 | PMID 28569090 Get It

Impaired brain clearance of amyloid-beta peptides (Aβ) 40 and 42 across the blood–brain barrier (BBB) is believed to be one of the pathways responsible for Alzheimer’s disease (AD) pathogenesis. Hyperinsulinemia prevalent in type II diabetes was shown to damage cerebral vasculature and increase Aβ accumulation in AD brain. However, there is no clarity on how aberrations in peripheral insulin levels affect Aβ accumulation in the brain. This study describes, for the first time, an intricate relation between plasma insulin and Aβ transport at the BBB. Upon peripheral insulin administration in wild-type mice: the plasma clearance of Aβ40 increased, but Aβ42 clearance reduced; the plasma-to-brain influx of Aβ40 increased, and that of Aβ42 reduced; and the clearance of intracerebrally injected Aβ40 decreased, whereas Aβ42 clearance increased. In hCMEC/D3 monolayers (in vitro BBB model) exposed to insulin, the luminal uptake and luminal-to-abluminal permeability of Aβ40 increased and that of Aβ42 reduced; the abluminal-to-luminal permeability of Aβ40 decreased, whereas Aβ42 permeability increased. Moreover, Aβ cellular trafficking machinery was altered. In summary, Aβ40 and Aβ42 demonstrated distinct distribution kinetics in plasma and brain compartments, and insulin differentially modulated their distribution. Cerebrovascular disease and metabolic disorders may disrupt this intricate homeostasis and aggravate AD pathology.
Neuroimaging biomarkers and impaired olfaction in cognitively normal individuals
Vassilaki, Maria , Christianson, Teresa J., Mielke, Michelle M. , Geda, Yonas E. , Kremers, Walter K. , Petersen, Ronald C. , Lowe, Val J. , Jack, Clifford R. , Roberts, Rosebud O., Machulda, Mary M. , Knopman, David S. , Jack, Clifford R , Mielke, Michelle M , Geda, Yonas E , Kremers, Walter K

Mayo Clinic

Annals of Neurology | May 23, 2017 | Volume: 81 | Issue: 6 | Pages: 871-882

10.1002/ana.24960 | PMID 28543731 Get It

Objective There is a need for inexpensive noninvasive tests to identify older healthy persons at risk for Alzheimer disease (AD) for enrollment in AD prevention trials. Our objective was to examine whether abnormalities in neuroimaging measures of amyloid and neurodegeneration are correlated with odor identification (OI) in the population‐based Mayo Clinic Study of Aging. Methods Cognitively normal (CN) participants had olfactory function assessed using the Brief Smell Identification Test (B‐SIT), underwent magnetic resonance imaging (n = 829) to assess a composite AD signature cortical thickness and hippocampal volume (HVa), and underwent 11 C‐Pittsburgh compound B (n = 306) and 18 fluorodeoxyglucose (n = 305) positron emission tomography scanning to assess amyloid accumulation and brain hypometabolism, respectively. The association of neuroimaging biomarkers with OI was examined using multinomial logistic regression and simple linear regression models adjusted for potential confounders. Results Among 829 CN participants (mean age = 79.2 years; 51.5% men), 248 (29.9%) were normosmic and 78 (9.4%) had anosmia (B‐SIT score < 6). Abnormal AD signature cortical thickness and reduced HVa were associated with decreased OI as a continuous measure (slope = −0.43, 95% confidence interval [CI] = −0.76 to −0.09, p = 0.01 and slope = −0.72, 95% CI = −1.15 to −0.28, p < 0.01, respectively). Reduced HVa, decreased AD signature cortical thickness, and increased amyloid accumulation were significantly associated with increased odds of anosmia. Interpretation Our findings suggest that OI may be a noninvasive, inexpensive marker for risk stratification, for identifying participants at the preclinical stage of AD who may be at risk for cognitive impairment and eligible for inclusion in AD prevention clinical trials. These cross‐sectional findings remain to be validated prospectively. Ann Neurol 2017;81:871–882
Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis
Zeydan, Burcu , Lowe, Val J. , Przybelski, Scott A. , Tosakulwong, Nirubol , Zuk, Samantha M., Senjem, Matthew L. , Gunter, Jeffrey L. , Roberts, Rosebud O., Mielke, Michelle M. , Benarroch, Eduardo E. , Rodriguez, Moses , Lesnick, Timothy G. , Petersen, Ronald C. , Jack, Clifford R. , Kantarci, Kejal , Kantarci, Orhun H. , Schwarz, Christopher G. , Machulda, Mary M. , Knopman, David S. , Jack, Clifford R , Mielke, Michelle M , Senjem, Matthew L , Kantarci, Kejal , Rodriguez, Moses , Zeydan, Burcu

Mayo Clinic

Multiple Sclerosis Journal | May 5, 2017 | Volume: 24 | Issue: 6 | Pages: 739-749

10.1177/1352458517707346 | PMID 28474977 Get It

Background: There is growing interest in white matter (WM) imaging with positron emission tomography (PET). Objectives: We studied the association of cognitive function in late multiple sclerosis (MS) with cortical and WM Pittsburgh compound-B PET (PiB-PET) binding. Methods: In the population-based Mayo Clinic Study of Aging, 24 of 4869 participants had MS (12 underwent PiB-PET). Controls were age and sex matched (5:1). We used automated or semi-automated processing for quantitative image analyses and conditional logistic regression for group differences. Results: MS patients had lower memory ( p = 0.03) and language ( p = 0.02) performance; smaller thalamic volumes ( p = 0.003); and thinner temporal ( p = 0.001) and frontal ( p = 0.045) cortices on magnetic resonance imaging (MRI) than controls. There was no difference in global cortical PiB standardized uptake value ratios between MS and controls ( p = 0.35). PiB uptake was lower in areas of WM hyperintensities compared to normal-appearing white matter (NAWM) in MS ( p = 0.0002). Reduced PiB uptake in both the areas of WM hyperintensities ( r = 0.65; p = 0.02) and NAWM ( r = 0.69; p = 0.01) was associated with decreased visuospatial performance in MS. Conclusion: PiB uptake in the cortex in late MS is not different from normal age-matched controls. PiB uptake in the WM in late MS may be a marker of the large network structures’ integrity such as those involved in visuospatial performance.
Contributions of imprecision inPET‐MRIrigid registration to imprecision in amyloidPETSUVRmeasurements
Schwarz, Christopher G. , Gunter, Jeffrey L. , Lowe, Val J. , Vemuri, Prashanthi , Senjem, Matthew L. , Petersen, Ronald C. , Jack, Clifford R. , Initiative, The Alzheimer's Disease Neuroimaging, Jones, David T. , Knopman, David S. , Initiative, The Alzheimer's Disease Neuroimaging, Jack, Clifford R , Schwarz, Christopher G , Vemuri, Prashanthi , Senjem, Matthew L

Mayo Clinic

Human Brain Mapping | April 22, 2017 | Volume: 38 | Issue: 7 | Pages: 3323-3336

10.1002/hbm.23622 | PMID 28432784 Get It

AbstractQuantitative measurement of β‐amyloid from amyloid PET scans typically relies on localizing target and reference regions by image registration to MRI. In this work, we present a series of simulations where 50 small random perturbations of starting location and orientation were applied to each subject's PET scan, and rigid registration usingspm_coregwas performed between each perturbed PET scan and its corresponding MRI. We then measured variation in the output PET‐MRI registrations and how this variation affected the resulting SUVR measurements. We performed these experiments using scans of 1196 participants, half using 18F florbetapir and half using 11C PiB. From these experiments, we measured the magnitude of the imprecision in the rigid registration steps used to localize measurement regions, and how this contributes to the overall imprecision in SUVR measurements. Unexpectedly, we found for both tracers that the imprecision in these measurements depends on the degree of amyloid tracer uptake, and thus also indirectly on Alzheimer's disease clinical status. We then examined common choices of reference regions, and we show that SUVR measurements using supratentorial white matter references are relatively resistant to this source of error. We also show that the use of partial volume correction further magnifies the effects of registration imprecision on SUVR measurements. Together, these results suggest that this rigid registration step is an attractive target for future work in improving measurement techniques.Hum Brain Mapp 38:3323–3336, 2017. ©2017 The Authors Human Brain Mapping Published by Wiley Periodicals, Inc.
Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals
Vemuri, Prashanthi , Lesnick, Timothy G. , Przybelski, Scott A. , Mielke, Michelle M. , Graff‐Radford, Jonathan , Murray, Melissa E. , Roberts, Rosebud O., Vassilaki, Maria , Lowe, Val J. , Petersen, Ronald C. , Jack, Clifford R. , Knopman, David S. , Machulda, Mary M. , Jones, David T. , Jack, Clifford R , Mielke, Michelle M , Vemuri, Prashanthi , Murray, Melissa E

Mayo Clinic

JAMA Neurology | April 18, 2017 | Volume: 74 | Issue: 6 | Pages: 718

10.1001/jamaneurol.2017.0244 | PMID 28418521 Get It

Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma
Leon‐Ferre, Roberto A. , Kottschade, Lisa A. , Block, Matthew S. , Dronca, Roxana , Creagan, Edward T. , Allred, Jacob B., Lowe, Val J. , McWilliams, Robert R. , Markovic, Svetomir N.

Mayo Clinic

Melanoma Research | March 14, 2017 | Volume: 27 | Issue: 4 | Pages: 335-341

10.1097/cmr.0000000000000344 | PMID 28296712 Get It

The optimal surveillance for patients with resected high-risk melanoma is controversial. Select locoregional or oligometastatic recurrences can be cured with salvage resection. Data on the ability of PET/CT to detect such recurrences are sparse. We evaluated whether surveillance PET/CT in patients with resected stage III–IV melanoma led to detection of clinically occult recurrences amenable to curative-intent salvage treatment. We retrospectively identified 1429 melanoma patients who underwent PET/CT between January 2008 and October 2012 at Mayo Clinic (Rochester, Minnesota). A total of 1130 were excluded because of stage I–II, ocular or mucosal melanoma, incomplete resection, PET/CT not performed for surveillance or performed at a different institution, and records not available. A total of 299 patients were eligible. Overall, 162 (52%) patients developed recurrence [locoregional: 77 (48%), distant: 85 (52%)]. The first recurrence was clinically occult in 98 (60%) and clinically evident in 64 (40%). Clinically evident recurrences were more often superficial (skin, subcutaneous, or nodal) or in the brain, whereas clinically occult recurrences more often visceral. Overall, 90% of all recurrences were detected by 2.8 years. In all, 70% of patients with recurrence underwent curative-intent salvage treatment (locoregional: 94%, distant: 48%), with similar rates for clinically occult versus clinically evident recurrences (66 vs. 75%, P=0.240). Overall survival was superior among those who underwent curative-intent salvage treatment [5.9 vs. 1.2 years; hazard ratio=4.27, 95% confidence interval (CI)=2.68–6.80; P<0.001], despite 79% developing recurrence again. PET/CT had high sensitivity (88%, 95% CI=79.94–93.31%), specificity (90%, 95% CI=88.56–91.56%), and negative predictive value (99%, 95% CI=98.46–99.52%). However, the positive predictive value was only 37% (95% CI=31.32–43.68%). In patients with resected stage III–IV melanoma, surveillance PET/CT detected a large proportion of clinically occult recurrences amenable to curative-intent salvage treatment. Despite a high rate of second relapse, curative-intent salvage treatment was associated with superior overall survival. Even though PET/CT had high sensitivity, specificity, and negative predictive value, positive predictive value was poor, highlighting the need for histologic confirmation of PET/CT-detected abnormalities.
Mapping prostate cancer (CaP) recurrence after prostatectomy with c-11 choline PET/CT and 3T pelvic MRI in the contemporary era.
Sobol, Ilya , Haloi, Rimki , Park, Sean Sunghun, Mynderse, Lance A. , Boorjian, Stephen A. , Thompson, R. Houston, Tollefson, Matthew K. , Gettman, Matthew T., Froemming, Adam T. , Lowe, Val J. , Frank, Igor, Karnes, R. Jeffrey , Kwon, Eugene D., Viers, Boyd R. , Davis, Brian J. , Quevedo, Fernando

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 34 | Issue: 2_suppl | Pages: 255-255

10.1200/jco.2016.34.2_suppl.255 Get It

255 Background: The purpose of this study was to identify site-specific recurrence patterns for patients (pts) with biochemical recurrence (BCR) after prostatectomy (RP) using C-11 Choline PET/CT (C11Ch) and 3T pelvic MRI with endorectal coil (pMRI). Methods: Between 2008 and 2006, 2,466 men underwent C11Ch and pMRI for BCR after RP. From this cohort, we identified 261 pts who received no adjuvant or salvage therapy (androgen deprivation or radiation). Suspected radiographic relapse was confirmed by biopsy (46%) or progression/response to treatment in concordance with subsequent rise/decline in PSA (54%). Results: Of the 261 men evaluated, 202 (75%) had positive pMRI, C11Ch or both. Seventy nine (39%), 105 (52%) and 18 (9%) pts had high, intermediate, and low risk CaP, respectively at RP. Median PSA at the time of positive scan was 2.3 ng/mL, with a median time from BCR to radiographic disease identification of 15 months. Of these 202 men, 67 (33%) harbored prostate fossa recurrence only, 44 (22%) had a combination of local and metastatic disease and 91 (45%) had metastatic disease without local recurrence. Forty (20%) pts had pelvic nodal recurrence only and 18 (9%) had perirectal nodal involvement. Median PSA for pts with local only recurrence, distant metastases only, and local + distant disease was 2.3, 2.7 and 2.2 ng/mL, respectively, with a median interval from BCR to positive scan of 16.7, 7.9 and 11 months. Imaging revealed that 33% to 66% of our cohort would have all sites of disease treated by salvage RT depending on the extent of the treatment field Conclusions: C11Ch and pMRI were used to identify recurrence patterns in pts with BCR after RP only. At median PSA of 2.3 ng/ml, our study demonstrates a low rate of local-only recurrence, higher than anticipated frequency of metastatic recurrence with peak frequency within the pelvic lymph nodes, and substantial perirectal recurrences. Despite the high rates of distant recurrences, 2/3 of our cohort had their disease limited to the pelvis and could be potential candidates for local therapies, including salvage radiation.
A robust biomarker of large‐scale network failure in Alzheimer's disease
Wiepert, Daniela A. , Lowe, Val J. , Graff‐Radford, Jonathan, Petersen, Ronald C. , Jones, David T. , Knopman, David S. , Boeve, Bradley F. , Graff‐Radford, Jonathan , Jack, Clifford R. , Jones, David T

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | January 25, 2017 | Volume: 6 | Issue: 1 | Pages: 152-161

10.1016/j.dadm.2017.01.004 | PMID 28275697 Get It

AbstractIntroductionBiomarkers for Alzheimer's disease (AD) pathophysiology have been developed that focus on various levels of brain organization. However, no robust biomarker of large‐scale network failure has been developed. Using the recently introduced cascading network failure model of AD, we developed the network failure quotient (NFQ) as a biomarker of this process.MethodsWe developed and optimized the NFQ using our recently published analyses of task‐free functional magnetic resonance imaging data in clinically normal (n = 43) and AD dementia participants (n = 28) from the Alzheimer's Disease Neuroimaging Initiative. The optimized NFQ (oNFQ) was then validated in a cohort spanning the AD spectrum from the Mayo Clinic (n = 218).ResultsThe oNFQ (d = 1.25, 95% confidence interval [1.25, 1.26]) had the highest effect size for differentiating persons with AD dementia from clinically normal participants. The oNFQ measure performed similarly well on the validation Mayo Clinic sample (d = 1.44, 95% confidence interval [1.43, 1.44]). The oNFQ was also associated with other available key biomarkers in the Mayo cohort.DiscussionThis study demonstrates a measure of functional connectivity, based on a cascading network failure model of AD, and was highly successful in identifying AD dementia. A robust biomarker of the large‐scale effects of AD pathophysiology will allow for richer descriptions of the disease process and its modifiers, but is not currently suitable for discriminating clinical diagnostic categories. The large‐scale network level may be one of the earliest manifestations of AD, making this an attractive target for continued biomarker development to be used in prevention trials.
Tau‐PET uptake: Regional variation in average SUVR and impact of amyloid deposition
Vemuri, Prashanthi , Lowe, Val J. , Senjem, Matthew L. , Kemp, Bradley J. , Schwarz, Christopher G. , Przybelski, Scott A. , Petersen, Ronald C. , Knopman, David S. , Machulda, Mary M. , Jack, Clifford R. , Schwarz, Christopher G , Vemuri, Prashanthi , Senjem, Matthew L

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | December 22, 2016 | Volume: 6 | Issue: 1 | Pages: 21-30

10.1016/j.dadm.2016.12.010 | PMID 28138510 Get It

AbstractIntroductionTau‐positron emission tomography (PET) imaging with AV1451 is sensitive to Alzheimer disease (AD)–related tau deposition in the brain. We (1) examined regional variation of average tau‐PET standardized uptake value ratios (SUVRs) in a young normal population (30–49 years) and corrected for the regional variability and (2) tested if the standardized values (z‐scores) scaled appropriately to capture regional Alzheimer‐specific (i.e., amyloid sensitive) tau‐PET changes in individuals aged 50+ years.MethodsWe identified 490 individuals (70 between 30–49 years as a reference group and 420 cognitively normal between 50–95 years of age) with tau‐PET and amyloid PET scans from the Mayo Clinic Study of Aging.ResultsThere was intrinsic regional variability in average tau‐PET SUVR with uptakes higher in some regions than others, even in the younger individuals who would have minimal or no neurofibrillary tangles. We corrected for this using region of interest–specific z‐scores based on the reference group. Amyloid and tau‐PET uptake were associated throughout the brain after adjusting for age, with the highest correlations in the medial temporal regions.DiscussionRegions with high‐average SUVR are not necessarily those with the greatest tau pathology. Standardization is therefore recommended. Standardization of the data “realigns” the data such that the regional tau z‐scores are informative of the disease process, that is, regions with high z‐scores now coincide with regions correlated with amyloid deposition. Medial temporal structures, specifically entorhinal cortex–tau, may be useful as an AD‐specific tau‐PET signature due to its sensitivity to amyloid.